- Conditions
- Incidence of Major Adverse Cardiac Events
- Interventions
- PCI with Synergy Stent
- Other
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 3,785
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Inflammatory Bowel Diseases, IBD
- Interventions
- TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 13
- States / cities
- La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
- Interventions
- Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Dinitrochlorobenzene
- Drug
- Lead sponsor
- The Honolulu Medical Group
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- REGN4659, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more
- Conditions
- Mucopolysaccharidosis II
- Interventions
- tividenofusp alfa
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
- Conditions
- Miscarriage, Stillbirth, Cholera
- Interventions
- Shanchol
- Biological
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 15 Years to 49 Years · Female only
- Enrollment
- 2,758 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate, Radiation Therapy
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infection
- Interventions
- rifampin
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 121 Days
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Cyanide Poisoning
- Interventions
- Stabilized Isoamyl Nitrite (SIAN)
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • Austin, Texas
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer
- Interventions
- MGC030
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- Behavioral · Drug
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm
- Interventions
- Zenith® t-Branch, Terumo Arch Branch
- Device
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2032
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- RO5095932, metformin, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Anaheim, California • Chula Vista, California • Fort Myers, Florida + 2 more
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
- Interventions
- Tegavivint
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Multiple Myeloma
- Interventions
- Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
- Interventions
- Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
- Behavioral · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2031
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan
- Procedure · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Duarte, California • Encinitas, California • Irvine, California + 21 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Aging
- Interventions
- Conventional tDCS, Optimized tDCS, Conventional Sham, Optimized Sham
- Device
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Roslindale, Massachusetts
- Conditions
- Parkinson's Disease
- Interventions
- MT101-5
- Drug
- Lead sponsor
- Mthera Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Healthy
- Interventions
- Pirtobrutinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida